Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OCAT

Ocata Therapeutics (OCAT) Stock Price, News & Analysis

Ocata Therapeutics logo

About Ocata Therapeutics Stock (NASDAQ:OCAT)

Advanced Chart

Key Stats

Today's Range
$8.47
$8.47
50-Day Range
N/A
52-Week Range
$3.06
$8.71
Volume
N/A
Average Volume
656,469 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive OCAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OCAT Stock News Headlines

Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
Induced Pluripotent Stem Cells Market by 2031
See More Headlines

OCAT Stock Analysis - Frequently Asked Questions

Ocata Therapeutics (NASDAQ:OCAT) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $0.04 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocata Therapeutics investors own include Antares Pharma (ATRS), Anavex Life Sciences (AVXL), Sarepta Therapeutics (SRPT), Athersys (ATHX), Prospect Capital (PSEC), Bristol-Myers Squibb (BMY) and Conatus Pharmaceuticals (CNAT).

Company Calendar

Last Earnings
8/06/2015
Today
4/19/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:OCAT
Previous Symbol
OTCMKTS:ACTC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:OCAT) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners